X

Trial Profile

ECOG S0008: A Phase III Trial of High Dose Interferon Alpha-2b Vs. Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha-2b (Primary) ; Interferon alpha-2b (Primary) ; Cisplatin; Dacarbazine; Filgrastim; Interleukin-2; Vinblastine
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Mar 2015 Biomarkers information updated
18 Sep 2012 Planned end date changed from 1 Jun 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
18 Sep 2012 Planned end date changed from 1 Jun 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com